...
首页> 外文期刊>Heart rhythm: the official journal of the Heart Rhythm Society >Hybrid epicardial-endocardial ablation using a pericardioscopic technique for the treatment of atrial fibrillation
【24h】

Hybrid epicardial-endocardial ablation using a pericardioscopic technique for the treatment of atrial fibrillation

机译:使用心包镜技术混合性心外膜-心内膜消融治疗房颤

获取原文
获取原文并翻译 | 示例

摘要

Background: Catheter ablation is an effective treatment for medically refractory, disabling atrial fibrillation (AF). Ablation success may be limited in patients with persistent or long-standing persistent AF. A pericardioscopic, hybrid epicardial-endocardial technique for AF ablation may be a preferred approach for such patients. Limited data are available using such an approach. Objective: To evaluate 1-year outcomes of a hybrid technique for AF ablation. Methods: A cohort of 101 patients underwent AF ablation using a transdiaphragmatic pericardioscopic, hybrid epicardial-endocardial technique. Patients were followed with 24-hour Holter monitors at 3-, 6-, and 12-month intervals. Symptom severity was assessed at baseline and follow-up by using the Canadian Cardiovascular Society Severity of Atrial Fibrillation scale. Results: Mean AF duration was 5.9 years; 47% were persistent and 37% were long-standing persistent. Mean left atrial size was 5.1 cm (range 3.3-7 cm). Overall, 12-month arrhythmia-free survival was 66.3% after a single ablation procedure and 70.5% including repeat ablation. Repeat ablation was required in 6% of the patients and antiarrhythmic drug therapy in 37% of the patients. Quality of life improved significantly and was durable over 12-month follow-up. There were 2 deaths, which occurred in the early postoperative period: one due to atrioesophageal fistula and the second due to sudden cardiac death without apparent cause by autopsy. Conclusions: We report the largest series to date of a hybrid epicardial-endocardial, stand-alone ablation procedure using a pericardioscopic technique for the treatment of AF. While respecting the identified complications, our results demonstrate a high potential for successful treatment in a challenging patient population with AF.
机译:背景:导管消融术是治疗难治性房颤(AF)的有效方法。持续性或长期性持续性房颤患者的消融成功可能受到限制。心包镜,混合心外膜心内膜技术用于房颤消融可能是此类患者的首选方法。使用这种方法可获得有限的数据。目的:评估混合消融技术的1年结局。方法:采用经dia膜心包镜,混合心外膜-心内膜技术对101例患者进行房颤消融。患者每隔3、6和12个月接受24小时动态心电图监测。症状严重程度在基线和随访时通过加拿大心血管学会心房颤动严重程度量表进行评估。结果:平均房颤持续时间为5.9年; 47%为持久性,37%为长期持久性。平均左心房大小为5.1厘米(范围为3.3-7厘米)。总体而言,单次消融术后12个月无心律失常生存率为66.3%,包括重复消融为70.5%。 6%的患者需要重复消融,而37%的患者需要抗心律失常药物治疗。生活质量显着改善,并且在12个月的随访中具有持久性。术后早期有2例死亡:一例是由于食管瘘引起的,另一例是由于心脏猝死而没有明显的尸检原因。结论:我们报道了迄今为止最大的一系列混合性心外膜-心内膜独立消融术,采用心包镜技术治疗房颤。在尊重已发现的并发症的同时,我们的结果表明在具有挑战性的房颤患者中成功治疗的潜力很大。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号